Clomiphene analysis

The Clomiphene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clomiphene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.

The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).

About Clomiphene 

Clomiphene, also known by the trade name Clomid, is an orally active, non-steroidal selective estrogen receptor modulator (SERM). It interacts with estrogen receptors and can exert estrogenic or anti-estrogenic effects depending on the target tissue. Clomiphene is used clinically to induce ovulation in selected patients with ovulatory dysfunction.

The compound is commonly administered as clomiphene citrate and consists of two geometric isomers, enclomiphene and zuclomiphene, which differ in their biological properties.

Key Features

• Targeted identification and quantification of clomiphene
• Suitable for pills, tablets, capsules, and raw API powders
• Analysis by HPLC
• Results for oral products reported in mg per tablet or capsule
• Results for raw API powders reported as percentage content
• Optional purity reporting in % (m/m) for raw API powders
• Minimum sample amount for raw API powders: 200 mg
• Average turnaround time of 7 business days

Analysis Parameters

• Target compound: Clomiphene
• Other name: Clomid
• CAS number: 911-45-5
• Testing method: HPLC
• Minimum amount of target compound for evaluation in oral products: 5 mg per pill, tablet, or capsule
• Minimum content of target compound for evaluation in raw API powders: 10%
• Result format for oral products: mg per tablet or capsule
• Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]
• Minimum sample amount for oral products: Tablets or capsules
• Minimum sample amount for raw API powders: 200 mg
• Average turnaround time: 7 business days

Important Notice

• This analysis is specifically intended for clomiphene. It does not automatically screen the sample for enclomiphene, zuclomiphene, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.
• For oral products, the minimum amount of clomiphene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.
• Purity reporting in % (m/m) is available only for raw API powders.

Optional Additional Analyses

The following optional laboratory services are available:

• Complete Raw Analytical Data
• Alternative Result Format: Purity in % (m/m) – only for raw API powders
• Batch Variance Testing
• Fentanyl Screening
• GC–MS Contamination Screening
• Heavy Metals Analysis (As, Cd, Pb, Hg)
• Additional Laboratory Report